A new analysis of the DETECT study results

A new analysis of the DETECT study results was recently published online in the Journal of Magnetic Resonance Imaging, with the title:

Comparison of gadobenate dimeglumine-enhanced breast MRI and gadopentetate dimeglumine-enhanced breast MRI with mammography and ultrasound for the detection of breast cancer.
Gilbert et al., J Magn Reson Imaging 2013. Article first published online: 4 NOV 2013. DOI: 10.1002/jmri.24434

The article, available online at is of relevance for the current debates in breast cancer diagnosis, as it clarifies the role of MRI vs conventional diagnostic modalities, such as mammography and ultrasound, to which the MRI exams were compared. The DETECT study, already published in 2011 in Radiology, had previously shown that gadobenate dimeglumine (MultiHance) is superior to gadopentetate dimeglumine (Magnevist) for breast cancer diagnosis.

The new analysis has shown that, for all the 3 blinded readers in the study, the sensitivity of breast MRI in cancer detection was significantly higher on MultiHance-enhanced MRI compared with mammography (p<0.0001), ultrasound (p<0.0001), and combined mammography and ultrasound (p<0.02).

Even more importantly, the article shows that:

  1. the same difference was not found for comparisons of gadopentetate-enhanced MRI with conventional techniques (p>0.05); in other words, breast MRI performed better than those conventional techniques only when it was performed with MultiHance.
  2. the three blinded readers also noted lower false positive detection rates on MultiHance-enhanced MRI than on gadopentetate-enhanced MRI and conventional imaging modalities; this result is of great importance, also in light of the ongoing debate on the specificity of breast MRI.